Skip to main content

Yancopoulos George's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 17, 2021

Accession no.
0001708138-21-000055
Filed
Aug 17, 2021
Trade date
Aug 13-16, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $31.3M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yancopoulos GeorgeCIK 0001226690Director, Officer (President and Chief Scientific)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 13, 2021Common StockSSaleDisposed−773$625.00−$483,125936,710Direct
Aug 16, 2021Common StockSSaleDisposed−46,925$625.25F2−$29,339,856.25889,785Direct
Aug 16, 2021Common StockSSaleDisposed−2,302$626.10F3−$1,441,282.2887,483Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 46,925 shares of Company stock on August 16, 2021 at prices ranging from $625.00 to $625.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 2,302 shares of Company stock on August 16, 2021 at prices ranging from $626.00 to $626.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)